Statement 5 Sep 2025

Statement on the publication of the 24th WHO Model List of Essential Medicines

Responding to the publication of the updated WHO Model List of Essential Medicines (EML), IFPMA Director General, Dr. David Reddy said: “The inclusion of innovative medicines on the updated EML highlights how scientific advances are transforming how we prevent, treat and cure disease, and reinforces the importance of ensuring patients everywhere can benefit from them. ...

Statement 27 Aug 2025

AMATA statement at 75th WHO AFRO: Progress report on the regional strategy on regulation of medical products in African region

On 27 August 2025, the African Medicines Agency Treaty Alliance submitted a statement on agenda item 16.8: Progress report on the regional strategy on regulation of medical products in African region, 2016-2025 at the 75th Session of the WHO Regional Committee for Africa. The African Medicines Agency Treaty Alliance (AMATA) commends the progress made under...

Statement 27 Aug 2025

75th WHO Regional Committee for Africa: Progress report on the implementation of the strategy for scaling up health innovations in the African region

On 27 August 2025 in Lusaka, Zambia, IFPMA delivered a statement at the 75th session of the WHO Regional Committee for Africa focused on Agenda item 16.2: Progress report on the implementation of the strategy for scaling up health innovations in the African region. IFPMA takes note of WHO AFRO’s Progress report on the implementation...

Statement 5 Aug 2025

Advancing a health-centric global plastics treaty

On 5 August 2025, IFPMA, together with Health Care Without Harm and the Global Self-Care Federation, published a joint statement on the global plastics treaty under negotation at the continued fifth session of the Intergovernmental Negotiating Committee (INC-5.2) in Geneva.

Infographic 23 Jul 2025

Streamlining samples management to strengthen health outcomes in Africa

Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...

Statement 11 Jul 2025

High-level interactive dialogue on the social, economic, and environmental determinants of health

On 11 July 2025 in New York at the UN Headquarters, IFPMA delivered a statement at the High-Level Dialogue on the Determinants of Health. Innovation in public health is essential to addressing the social, economic, and environmental determinants of health. IFPMA welcomes this dialogue and underscores the importance of collaboration to address complex health challenges,...

Position paper 8 Jul 2025

Reimagining our response to non-communicable diseases (NCDs) and mental health

Reflections on the draft Political Declaration for the UN High Level Meeting on the Prevention and Control of NCDs and the Promotion of Mental Health and Well-being This advocacy brief outlines three areas where industry seeks more explicit commitments from governments: Leverage health innovation Strengthen prevention and early action for lifelong health Address multimorbidity through...

Expert insight 30 Jun 2025

Getting procurement right: sustainable and secure supply chains that support access to medicines

During the OECD Global Public Procurement Forum, leaders will discuss how public procurement can be used to unlock social, environmental and economic benefits. Sustainable procurement can be an opportunity for collaboration between healthcare systems and industry to get this balance right. However, for this approach to be successful, it must be carefully implemented. Without a thoughtful design, procurement policies can inadvertently introduce requirements that disrupt supply chains, limit product availability, and put the brakes on future innovation. In this blog, IFPMA shares a set of core principles that can guide policy design on sustainable procurement.

Press release 26 Jun 2025

Groups representing patients, healthcare professionals and pharmaceutical industry author new principle on use of AI in healthcare

On 26 June 2025, six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have adopted the first joint ethical principle in the healthcare industry on the responsible use of health data and technology, including artificial intelligence.

Report 26 Jun 2025

International consensus framework for ethical collaboration in health

The International Consensus Framework for Ethical Collaboration in Health is the only global platform of its kind, routinely convening diverse health stakeholders in support of high-quality patient care. First established in 2014, the Consensus Framework was revised in 2024 to coincide with its tenth anniversary and adopted in 2025 to include a new principle, on responsible use of health data and technology. This reflects a growing importance of digital health and artificial intelligence, and a need for ethics to evolve alongside innovation.

Statement 25 Jun 2025

The pharmaceutical industry supports Gavi’s high-level pledging meeting

On 25 June 2025, Gavi, the Vaccine Alliance, is co-hosting the Global Summit: Health & Prosperity through Immunization in support of its next five-year strategic period, in partnership with the European Union and the Gates Foundation.

External study 24 Jun 2025

Key access pathways and bottlenecks for medicines in LMICs

Medicines and vaccines have transformed the way we prevent, treat, and cure diseases. Bringing these to people around the world requires more than scientific breakthroughs – it demands collaboration across the entire innovation and access pathway. From discovery and development to regulatory approval, supply, procurement and local delivery, each step plays a critical role in...